title: Efficacies of antiherpesvirus nucleosides against two strains of herpes simplex virus type 1 in Vero and human embryo lung fibroblast cells.
abstract: Antiviral activities of five nucleoside analogs against the VR-3 and WT-34 strains of herpes simplex virus type 1 (HSV-1) were investigated in Vero and human embryo lung fibroblast (HEL) cells. In HEL cells, the compounds showed antiviral activities against both strains of HSV-1, but in Vero cells, the antiviral activities of the compounds were reduced in proportion to their antiviral indexes (the 50% inhibitory dose [ID50] for cell growth divided by the 50% plaque reduction dose for virus). The ratio of the ID50 in Vero cells to the ID50 in HEL cells was larger in VR-3-infected cells than in WT-34-infected cells. The following results were obtained. (i) Thymidine kinase (TK; EC 2.7.1.21) activity in the VR-3- or WT-34-infected Vero cells was about half that in VR-3- or WT-34-infected HEL cells. Induction of viral TK was especially low in the VR-3-infected Vero cells. (ii) The ID50 of the plaque reduction assay in hypoxanthine, aminopterin, and thymidine medium revealed that the activity of cellular thymidylate synthetase (EC 2.1.1.45) was important in viral replication in VR-3-infected Vero cells. (iii) The VR-3-infected cells required larger thymidine and thymidine phosphate pools for viral replication than the WT-34-infected cells did, although uptake of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil into infected cells was equal for both strains. (iv) In the VR-3-infected Vero cells, the quantity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil triphosphate was smaller than that in VR-3-infected HEL cells and WT-34-infected Vero and HEL cells.
authors.affiliation: Department of Microbiology, Asahikawa Medical College, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Suzutani
authors.forename: H
authors.initials: H
authors.lastname: Machida
authors.forename: T
authors.initials: T
authors.lastname: Sakuma
mesh_terms: D000212:Acyclovir / Q000494:pharmacology; D000630:Aminopterin / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives / Q000494:pharmacology; D001087:Arabinonucleosides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts; D006801:Humans; D007065:Idoxuridine / Q000494:pharmacology; D008168:Lung; D009705:Nucleosides / Q000378:metabolism / Q000494:pharmacology*; D018139:Simplexvirus / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D013936:Thymidine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D014709:Vero Cells; D014740:Vidarabine / Q000494:pharmacology
chemical_list: D000998:Antiviral Agents; D001087:Arabinonucleosides; D009705:Nucleosides; D001086:Arabinofuranosyluracil; C031368:sorivudine; D014740:Vidarabine; D000630:Aminopterin; D007065:Idoxuridine; C010032:thymine arabinoside; D013936:Thymidine; D000212:Acyclovir